Date:10/13/2011

device-to-device comparisons; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Media Contacts:
Dana Banks
Phone: (949) 297-7348
Email: dbanks@masimo.com

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care… by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine  are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN are under license from University HealthSystem Consortium.

'/>"/>

SOURCE Masimo Corporation Copyright©2010 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7
Related medicine technology :

1. Masimo rainbow Acoustic Monitoring Technology Cleared for Market in Japan
2. Published Study Demonstrates the Absolute and Trend Accuracy of Masimo Noninvasive and Continuous Total Hemoglobin (SpHb) Monitoring in Intensive Care Unit Patients
3. Shriners Hospitals for Children® - Honolulu: First in Hawaii to Implement Masimo Noninvasive Hemoglobin Monitoring Technology
4. Masimo Pronto-7™ Receives Japanese and Canadian Regulatory Clearances
5. Masimo to Present at Morgan Stanley Global Healthcare Conference
6. Masimo Obtains CE Mark for SEDLine, Launches EEG-Based Brain Function Monitors in European Market
7. Masimo Reports Second Quarter 2011 Financial Results
8. Masimo Announces Adoption of Stock Repurchase Program
9. Masimo Introduces Pronto-7™ Internationally and Lifts Voluntary Recall
10. Masimo to Report Second Quarter 2011 Financial Results after Market Close on August 9, 2011
11. Masimo and Dartmouth-Hitchcock Medical Center, First Cross-Industry Collaborative Honored With the Institute for Technology and Healthcare Clinical Application Award